Target Name: KRT16P6
NCBI ID: G353194
Other Name(s): keratin 16 pseudogene 6 | lncKRT16P6 | LOC353194 | Keratin pseudogene

KRT16P6: A Potential Drug Target and Biomarker

Keratin 16 (K16) is a cytoskeleton protein that plays a crucial role in the organization and stability of hair and nails. It is composed of 16 distinct subunits that are responsible for maintaining the structural integrity of the cytoskeleton. The K16 gene has four exons, but only three functional ones due to a frameshift mutation. This gene has been identified as a potential drug target and biomarker due to its unique expression patterns in various tissues and its involvement in several diseases, including cancer.

The K16 gene has been shown to be expressed in a variety of tissues, including hair, scalp, skin, and nail. It is primarily expressed in the basal layer of the epidermis and the epidermis, where it is involved in the formation of the hair and nail matrix. In addition, it is also expressed in the dermis, where it is involved in tissue repair and regeneration following injury or inflammation.

KRT16P6 has been shown to be involved in several diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. Its involvement in these diseases has led to its potential as a drug target.

One of the potential drug targets of KRT16P6 is its role in cancer. The K16 gene has been shown to be involved in the development and progression of several types of cancer, including skin and scalp cancer. of neuroblastoma, a type of cancer that affects children, as well as with the development of malignant melanoma, a type of skin cancer.

In addition to its involvement in cancer, KRT16P6 has also been shown to be involved in neurodegenerative diseases. The K16 gene has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. be expressed in the brains of individuals with these conditions and to play a role in the development of neurofibrillary tangles and neurodegeneration.

Finally, KRT16P6 has also been shown to be involved in autoimmune disorders. The K16 gene has been shown to be involved in the development and progression of autoimmune disorders, including rheumatoid arthritis and psoriasis. It has been shown to be expressed in the tissues of individuals with these conditions and to play a role in the development of autoimmune disease.

In conclusion, KRT16P6 is a gene that has been identified as a potential drug target and biomarker due to its unique expression patterns in various tissues and its involvement in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of KRT16P6 in these diseases and to develop effective treatments.

Protein Name: Keratin 16 Pseudogene 6

More Common Targets

KRT17 | KRT17P1 | KRT17P2 | KRT17P3 | KRT17P5 | KRT17P7 | KRT18 | KRT18P1 | KRT18P12 | KRT18P13 | KRT18P16 | KRT18P17 | KRT18P19 | KRT18P22 | KRT18P23 | KRT18P24 | KRT18P27 | KRT18P28 | KRT18P29 | KRT18P31 | KRT18P33 | KRT18P34 | KRT18P4 | KRT18P40 | KRT18P41 | KRT18P42 | KRT18P44 | KRT18P48 | KRT18P49 | KRT18P5 | KRT18P50 | KRT18P51 | KRT18P55 | KRT18P59 | KRT18P6 | KRT18P62 | KRT19 | KRT19P2 | KRT19P3 | KRT2 | KRT20 | KRT222 | KRT23 | KRT24 | KRT25 | KRT26 | KRT27 | KRT28 | KRT3 | KRT31 | KRT32 | KRT33A | KRT33B | KRT34 | KRT35 | KRT36 | KRT37 | KRT38 | KRT39 | KRT4 | KRT40 | KRT42P | KRT5 | KRT6A | KRT6B | KRT6C | KRT7 | KRT7-AS | KRT71 | KRT72 | KRT73 | KRT73-AS1 | KRT74 | KRT75 | KRT76 | KRT77 | KRT78 | KRT79 | KRT8 | KRT80 | KRT81 | KRT82 | KRT83 | KRT84 | KRT85 | KRT86 | KRT87P | KRT89P | KRT8P10 | KRT8P11 | KRT8P12 | KRT8P14 | KRT8P16 | KRT8P17 | KRT8P18 | KRT8P22 | KRT8P23 | KRT8P25 | KRT8P26 | KRT8P29